Literature DB >> 19462983

Cancer, chemistry, and the cell: molecules that interact with the neurotensin receptors.

Rebecca M Myers1, James W Shearman, Matthew O Kitching, Antonio Ramos-Montoya, David E Neal, Steven V Ley.   

Abstract

The literature covering neurotensin (NT) and its signalling pathways, receptors, and biological profile is complicated by the fact that the discovery of three NT receptor subtypes has come to light only in recent years. Moreover, a lot of this literature explores NT in the context of the central nervous system and behavioral studies. However, there is now good evidence that the up-regulation of NT is intimately involved in cancer development and progression. This Review aims to summarize the isolation, cloning, localization, and binding properties of the accepted receptor subtypes (NTR1, NTR2, and NTR3) and the molecules known to bind at these receptors. The growing role these targets are playing in cancer research is also discussed. We hope this Review will provide a useful overview and a one-stop resource for new researchers engaged in this field at the chemistry-biology interface.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462983     DOI: 10.1021/cb900038e

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  22 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

2.  Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells.

Authors:  Ulrike Olszewski; Robert Zeillinger; Klaus Geissler; Gerhard Hamilton
Journal:  Lung Cancer (Auckl)       Date:  2010-09-04

3.  Identification and functional characterization of a stable, centrally active derivative of the neurotensin (8-13) fragment as a potential first-in-class analgesic.

Authors:  Francis M Hughes; Brooke E Shaner; Lisa A May; Lyndsay Zotian; Justin O Brower; R Jeremy Woods; Michael Cash; Dustin Morrow; Fabienne Massa; Jean Mazella; Thomas A Dix
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

4.  Characterization of the substrate specificity of human carboxypeptidase A4 and implications for a role in extracellular peptide processing.

Authors:  Sebastian Tanco; Xin Zhang; Cain Morano; Francesc Xavier Avilés; Julia Lorenzo; Lloyd D Fricker
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

5.  Imidazole-derived agonists for the neurotensin 1 receptor.

Authors:  Paul M Hershberger; Michael P Hedrick; Satyamaheshwar Peddibhotla; Arianna Mangravita-Novo; Palak Gosalia; Yujie Li; Wilson Gray; Michael Vicchiarelli; Layton H Smith; Thomas D Y Chung; James B Thomas; Marc G Caron; Anthony B Pinkerton; Lawrence S Barak; Gregory P Roth
Journal:  Bioorg Med Chem Lett       Date:  2013-11-21       Impact factor: 2.823

6.  Synthesis of a (68)ga-labeled peptoid-Peptide hybrid for imaging of neurotensin receptor expression in vivo.

Authors:  Simone Maschauer; Jürgen Einsiedel; Carsten Hocke; Harald Hübner; Torsten Kuwert; Peter Gmeiner; Olaf Prante
Journal:  ACS Med Chem Lett       Date:  2010-05-21       Impact factor: 4.345

7.  Synthesis and Evaluation of 64Cu-DOTA-NT-Cy5.5 as a Dual-Modality PET/Fluorescence Probe to Image Neurotensin Receptor-Positive Tumor.

Authors:  Huaifu Deng; Hui Wang; Mengzhe Wang; Zibo Li; Zhanhong Wu
Journal:  Mol Pharm       Date:  2015-07-21       Impact factor: 4.939

8.  Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells.

Authors:  Pei Xiao; Xinxin Long; Lijie Zhang; Yingnan Ye; Jincheng Guo; Pengpeng Liu; Rui Zhang; Junya Ning; Wenwen Yu; Feng Wei; Jinpu Yu
Journal:  Oncoimmunology       Date:  2018-03-13       Impact factor: 8.110

9.  Conformational Changes in Tyrosine 11 of Neurotensin Are Required to Activate the Neurotensin Receptor 1.

Authors:  Fabian Bumbak; Trayder Thomas; Billy J Noonan-Williams; Tasneem M Vaid; Fei Yan; Alice R Whitehead; Shoni Bruell; Martina Kocan; Xuan Tan; Margaret A Johnson; Ross A D Bathgate; David K Chalmers; Paul R Gooley; Daniel J Scott
Journal:  ACS Pharmacol Transl Sci       Date:  2020-04-29

10.  Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.

Authors:  Yinnong Jia; Wen Shi; Zhengyuan Zhou; Nilesh K Wagh; Wei Fan; Susan K Brusnahan; Jered C Garrison
Journal:  Nucl Med Biol       Date:  2015-07-29       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.